Compare Crocs, Inc. (CROX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Intuitive Surgical, Inc. — how do they compare? Crocs, Inc. trades at $131.61 (market cap $6.63B), while Intuitive Surgical, Inc. trades at $400.69 (market cap $138.97B). The key difference: Intuitive Surgical, Inc. is far larger — about 21× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| CROX | ISRG | |
|---|---|---|
Market Cap | $6.63B | $138.97B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $592.85 |
52-Week Low | $73.39 | $332.02 |
Enterprise Value | $8.14B | $133.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $136.62, up 1.82% with strong technical momentum and bullish moving averages. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $4.55 exceeding expectations. Despite a net loss in 2025 due to tax impacts, profitability metrics remain robust with 57.47% gross margins and 42.3% ROE. Recent news highlights tax strategy scrutiny but also strong DTC growth and raised 2026 guidance.
The stock presents value with a 12.12 P/E ratio below industry averages, supported by analyst consensus of $140.43 price target. Key risks include HEYDUDE brand weakness, tariff pressures, and ongoing tax scrutiny. Upside potential exists from international expansion and direct-to-consumer growth, though near-term volatility may persist around earnings.
Intuitive Surgical (ISRG) trades at $378.81, up 1.36% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bullish technical signals despite premium valuations (P/E 43.44, P/S 12.35), supported by robust revenue growth reaching $10.06B in 2025 and expanding profit margins of 28.45%. Recent news highlights da Vinci 5 adoption driving procedure growth beyond urology.
Outlook remains positive with 68% analyst buy ratings and $519.05 price target suggesting 37% upside. Key risks include competitive pressure from Medtronic/J&J robots and potential U.S. procedure softness. The combination of durable demand and innovation pipeline supports long-term growth potential for MedTech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
